Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 8,141 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Clear all
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood

NCT00823433
View directory record Official record
Conditions
Group B Streptococcus
Interventions
oral penicillin V
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)

NCT07199452
View directory record Official record
Conditions
Healthy
Interventions
MK-4646, Rifabutin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 21, 2026, 4:01 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder

NCT01774747
View directory record Official record
Conditions
Healthy
Interventions
DSP-1053, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 21, 2026, 4:01 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

NCT07065747
View directory record Official record
Conditions
Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
5 Years to 85 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes

NCT01045447
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
24
States / cities
Fresno, California • Waterbury, Connecticut • Boynton Beach, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects

NCT04196101
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Pelham, Alabama • Anaheim, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 21, 2026, 4:01 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease

NCT04311112
View directory record Official record
Conditions
Retinal Disorder
Interventions
Placebos, ZA Low dose, ZA high dose
Drug
Lead sponsor
Retinagenix Holdings
Industry
Eligibility
6 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 1 Interventional Results available

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

NCT02015819
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor, Anaplastic Oligoastrocytoma
Interventions
E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 21, 2026, 4:01 AM EDT
Withdrawn Phase 2 Interventional

IV Acetaminophen in Children Undergoing Palatoplasty

NCT01760330
View directory record Official record
Conditions
Cleft Palate
Interventions
IV acetaminophen, Placebo
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Hygiene Intervention for Adolescents

NCT05158465
View directory record Official record
Conditions
Oral Hygiene
Interventions
Motivational Interviewing
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
14 Years to 19 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 1 Interventional

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

NCT00948467
View directory record Official record
Conditions
Advanced Non-hematologic Malignancies, Advanced Metastatic Melanoma
Interventions
TAK-733
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Detriot, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 21, 2026, 4:01 AM EDT
Completed No phase listed Observational

Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder

NCT06256367
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Birmingham, Alabama • Beverly Hills, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01694771
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
90
States / cities
Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 21, 2026, 4:01 AM EDT
Terminated Early Phase 1 Interventional

Gastrointestinal STRING Test With Oral Immunotherapy

NCT04943744
View directory record Official record
Conditions
Eosinophilic Disorder, Food Allergy
Interventions
Entero-tracker, omalizumab, dupliumab
Device · Biological
Lead sponsor
Stanford University
Other
Eligibility
5 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 2 Interventional

PTC124 for Cystic Fibrosis

NCT00234663
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
PTC124
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2009 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Not applicable Interventional

A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

NCT00002293
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Nystatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Birmingham, Alabama • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 21, 2026, 4:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparison of Root Canal Desinfection Protocols

NCT07439614
View directory record Official record
Conditions
Periapical Periodontitis
Interventions
Desinfection device, Analytical microbiological methods
Device
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Not applicable Interventional Results available

Low-Level Laser Therapy for Prevention of Oral Mucositis

NCT02723604
View directory record Official record
Conditions
Mucositis
Interventions
Low Level Laser Therapy
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

NCT03292484
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
1 Year to 55 Years
Enrollment
911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
65
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)

NCT06688045
View directory record Official record
Conditions
Healthy
Interventions
Nemtabrutinib, Itraconazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 21, 2026, 4:01 AM EDT
Terminated Phase 3 Interventional Results available

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

NCT01829477
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
TAK-875, TAK-875 Placebo, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
38
States / cities
Muscle Shoals, Alabama • Phoenix, Arizona • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 21, 2026, 4:01 AM EDT
Terminated Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

NCT05660265
View directory record Official record
Conditions
Hematologic Diseases, Anaemia, Sickle Cell
Interventions
GSK4172239D, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Not applicable Interventional Results available

Low-Level Laser Therapy for Prevention of Oral Mucositis

NCT02682992
View directory record Official record
Conditions
Mucositis
Interventions
Low Level Laser Therapy
Device
Lead sponsor
David A. Clump, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 21, 2026, 4:01 AM EDT
Withdrawn Phase 2 Interventional

Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19

NCT04344236
View directory record Official record
Conditions
COVID-19
Interventions
Saline oral/nasal rinse, 0.5% Povidone/Iodine oral/nasal rinse, 0.12% Chlorhexidine oral/nasal rinse
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 21, 2026, 4:01 AM EDT